Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer

Fig. 3

Validation of identified markers in cancer derived graft (CDG) models of pancreatic cancer. a PCA plot showing that Mucin-specific O-Glycosylation signature distinguish cancer derived grafts (CDG) PDAC murine cell lines DT4313, FC1242, FC1245 analysed for RNAseq. (DIM1, 74.6%, DIM2. 18.8%). Arrows showing Gcnt3, Muc1 and Muc5ac contributions to variance; b Gcnt3, Muc1 and Muc5ac expression in CDG cells

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us